Intra-Cellular Therapies (ITCI) Short Interest Ratio & Short Volume $85.64 +2.29 (+2.75%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Intra-Cellular Therapies Short Interest DataIntra-Cellular Therapies (ITCI) has a short interest of 2.36 million shares. This marks a -2.48% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.4, indicating that it would take 4.4 days of the average trading volume of 860,091 shares to cover all short positions.Current Short Interest2,360,000 sharesPrevious Short Interest2,420,000 sharesChange Vs. Previous Month-2.48%Dollar Volume Sold Short$200.01 millionShort Interest Ratio4.4 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares106,020,000 sharesPercentage of Shares Shorted2.23%Today's Trading Volume407,787 sharesAverage Trading Volume860,091 sharesToday's Volume Vs. Average47% Short Selling Intra-Cellular Therapies? Sign up to receive the latest short interest report for Intra-Cellular Therapies and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartITCI Short Interest Over TimeITCI Days to Cover Over TimeITCI Percentage of Float Shorted Over Time Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Intra-Cellular Therapies Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20242,360,000 shares $200.01 million -2.5%N/A4.4 $84.75 10/15/20242,420,000 shares $180.80 million -6.6%N/A4.5 $74.71 9/30/20242,590,000 shares $189.51 million +0.8%N/A4.3 $73.17 9/15/20242,570,000 shares $193.73 million +5.8%N/A2.8 $75.38 8/31/20242,430,000 shares $178.07 million -4.3%N/A2.4 $73.28 8/15/20242,540,000 shares $191.19 million +2.0%N/A2.4 $75.27 Get the Latest News and Ratings for ITCI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. 7/31/20242,490,000 shares $196.01 million -14.7%N/A2.2 $78.72 7/15/20242,920,000 shares $229.77 million -29.5%N/A2.6 $78.69 6/30/20244,140,000 shares $283.55 million +11.0%N/A3.2 $68.49 6/15/20243,730,000 shares $252.78 million -6.8%N/A3.6 $67.77 5/31/20244,000,000 shares $268.96 million -12.1%N/A4.3 $67.24 5/15/20244,550,000 shares $304.12 million +24.0%N/A4.8 $66.84 4/30/20243,670,000 shares $263.54 million +2.2%N/A3.8 $71.81 4/15/20243,590,000 shares $232.49 million +3.5%N/A3.7 $64.76 3/31/20243,470,000 shares $240.12 million +4.8%N/A4.5 $69.20 3/15/20243,310,000 shares $214.42 million -10.5%N/A4.1 $64.78 2/29/20243,700,000 shares $257.22 million -4.2%N/A4.3 $69.52 2/15/20243,860,000 shares $289.08 million -5.2%N/A4.4 $74.89 1/31/20244,070,000 shares $274.07 million +16.0%N/A4.9 $67.34 1/15/20243,510,000 shares $232.92 million -7.9%N/A3.8 $66.36 12/31/20233,810,000 shares $272.87 million +5.8%N/A4 $71.62 12/15/20233,600,000 shares $235.58 million -8.4%N/A3.9 $65.44 11/30/20233,930,000 shares $241.18 million +15.3%N/A4.5 $61.37 11/15/20233,410,000 shares $193.31 million +7.9%N/A4.1 $56.69 10/31/20233,160,000 shares $157.24 million +17.9%N/A3.9 $49.76 10/15/20232,680,000 shares $143.81 million -4.6%N/A3.9 $53.66 9/30/20232,810,000 shares $146.37 million +26.0%N/A4.3 $52.09 9/15/20232,230,000 shares $122.72 million -12.6%N/A3.5 $55.03 8/31/20232,550,000 shares $141.58 million +0.4%N/A4 $55.52 8/15/20232,540,000 shares $146.86 million +25.1%N/A4 $57.82 7/31/20232,030,000 shares $125.54 million -16.8%N/A3.1 $61.84 7/15/20232,440,000 shares $154.99 million -6.2%N/A3.4 $63.52 6/30/20232,600,000 shares $164.63 million -22.2%N/A3.5 $63.32 6/15/20233,340,000 shares $214.66 million -2.9%N/A4 $64.27 5/31/20233,440,000 shares $204.27 million -3.4%N/A4.2 $59.38 5/15/20233,560,000 shares $231.08 million +21.9%N/A4 $64.91 4/30/20232,920,000 shares $181.48 million -9.6%N/A3.3 $62.15 4/15/20233,230,000 shares $194.48 million -3.0%N/A3.9 $60.21 3/31/20233,330,000 shares $180.32 million +27.6%N/A4.1 $54.15 3/15/20232,610,000 shares $114.32 million -21.2%N/A3.9 $43.80New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! 2/28/20233,310,000 shares $162.29 million +37.9%N/A5 $49.03 2/15/20232,400,000 shares $120 million -8.8%N/A4 $50.00 1/31/20232,630,000 shares $126.03 million +1.5%N/A4.6 $47.92 1/15/20232,590,000 shares $124.40 million -19.3%N/A4.1 $48.03 12/30/20223,210,000 shares $169.87 million +7.4%N/A5.1 $52.92 12/15/20222,990,000 shares $154.97 million +7.2%N/A4.6 $51.83 11/30/20222,790,000 shares $151.27 million -12.3%N/A4.1 $54.22 11/15/20223,180,000 shares $161.10 million -21.7%N/A4.5 $50.66 10/31/20224,060,000 shares $185.42 million +1.0%N/A5.3 $45.67 10/15/20224,020,000 shares $188.82 million -1.5%N/A5.5 $46.97 9/30/20224,080,000 shares $189.84 million +7.4%N/A5.6 $46.53 9/15/20223,800,000 shares $192.01 million +15.5%N/A5.1 $50.53 8/31/20223,290,000 shares $165.36 million -12.0%N/A4.4 $50.26 8/15/20223,740,000 shares $196.46 million +12.0%N/A5 $52.53 7/31/20223,340,000 shares $180.76 million -10.0%N/A4.1 $54.12 7/15/20223,710,000 shares $204.98 million +1.6%N/A4.7 $55.25 6/30/20223,650,000 shares $208.34 million +1.7%N/A4.3 $57.08 6/15/20223,590,000 shares $202.94 million +15.1%8.1%4.1 $56.53 5/31/20223,120,000 shares $179.09 million -18.8%N/A3.6 $57.40 5/15/20223,840,000 shares $226.94 million +15.0%N/A4 $59.10 4/30/20223,340,000 shares $169.04 million -12.1%N/A3.5 $50.61 4/15/20223,800,000 shares $244.34 million -1.3%N/A3.8 $64.30 3/31/20223,850,000 shares $235.58 million -10.5%N/A3.7 $61.19 3/15/20224,300,000 shares $250.99 million -11.9%N/A3.3 $58.37 2/28/20224,880,000 shares $270.74 million +1.2%N/A3.9 $55.48 2/15/20224,820,000 shares $269.92 million +1.9%6.6%4 $56.00 1/31/20224,730,000 shares $224.63 million +5.6%6.5%4.3 $47.49 1/15/20224,480,000 shares $192.95 million -1.1%N/A4.3 $43.07 12/31/20214,530,000 shares $237.10 million +22.8%6.2%4.9 $52.34 12/15/20213,690,000 shares $137.30 million +2.2%5.1%5.8 $37.21 11/30/20213,610,000 shares $146.13 million -2.2%5.0%8.1 $40.48 11/15/20213,690,000 shares $148.52 million -12.4%5.1%8.5 $40.25 10/29/20214,210,000 shares $181.32 million -21.2%5.8%9.5 $43.07 10/15/20215,340,000 shares $209.86 million -7.5%7.4%12.6 $39.30 9/30/20215,770,000 shares $215.11 million -1.4%8.0%13.4 $37.28 9/15/20215,850,000 shares $195.80 million No Change8.1%12.2 $33.47 8/31/20215,850,000 shares $194.22 million +7.0%8.1%12.1 $33.20 8/13/20215,470,000 shares $158.79 million -2.5%7.5%11.2 $29.03 7/30/20215,610,000 shares $192.59 million -2.8%7.8%11.3 $34.33 7/15/20215,770,000 shares $216.43 million +11.6%8.0%11.6 $37.51 6/30/20215,170,000 shares $211.04 million -12.2%7.2%10.1 $40.82 6/15/20215,890,000 shares $255.10 million -5.9%8.2%12.3 $43.31 5/28/20216,260,000 shares $246.71 million -8.4%8.7%12.9 $39.41 5/14/20216,830,000 shares $258.58 million No ChangeN/A13 $37.86 4/30/20216,830,000 shares $235.43 million +9.5%N/A12.1 $34.47 4/15/20216,240,000 shares $201.36 million -0.5%N/A10.8 $32.27 3/31/20216,270,000 shares $203.84 million -1.1%N/A10.4 $32.51 3/15/20216,340,000 shares $231.66 million -1.4%N/A9.5 $36.54 2/26/20216,430,000 shares $229.42 million +1.3%N/A9.2 $35.68 2/12/20216,350,000 shares $247.97 million -4.8%N/A8.6 $39.05New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! 1/29/20216,670,000 shares $214.84 million -3.5%N/A8.8 $32.21 1/15/20216,910,000 shares $235.91 million -8.7%N/A9 $34.14 12/31/20207,570,000 shares $243.91 million +11.7%N/A10 $32.22 12/15/20206,780,000 shares $171.33 million +7.8%N/A8.3 $25.27 11/30/20206,290,000 shares $157.12 million +9.0%N/A3.3 $24.98 11/15/20205,770,000 shares $154.46 million +5.5%N/A3.1 $26.77 10/30/20205,470,000 shares $131.17 million -7.3%N/A3 $23.98 10/15/20205,900,000 shares $153.11 million +0.5%N/A3.3 $25.95 9/30/20205,870,000 shares $150.62 million -12.9%N/A3.2 $25.66 9/15/20206,740,000 shares $204.56 million +26.2%N/A3.7 $30.35 8/31/20205,340,000 shares $97.29 million +7.9%N/A3.6 $18.22 8/14/20204,950,000 shares $95.78 million +2.1%N/A6.2 $19.35 7/31/20204,850,000 shares $96.18 million -5.1%N/A5.6 $19.83 7/15/20205,110,000 shares $120.75 million -3.8%N/A5.9 $23.63 6/30/20205,310,000 shares $133.71 million +7.7%N/A6.2 $25.18 6/15/20204,930,000 shares $99.34 million +0.2%N/A5.9 $20.15 5/29/20204,920,000 shares $102.73 million -10.2%N/A5.9 $20.88 5/15/20205,480,000 shares $121.05 million +1.7%N/A6.5 $22.09 4/30/20205,390,000 shares $95.24 million +6.5%N/A6.4 $17.67 4/15/20205,060,000 shares $83.24 million No ChangeN/A5.6 $16.45 3/31/20205,060,000 shares $89.82 million +3.9%N/A3.8 $17.75 3/13/20204,869,200 shares $80.20 million +1.9%N/A6 $16.47 2/28/20204,780,000 shares $63.67 million +7.4%N/A1.7 $13.32 2/14/20204,450,000 shares $86.64 million +2.1%N/A1.5 $19.47 1/31/20204,360,000 shares $96.97 million -33.3%9.3%1.5 $22.24 1/15/20206,540,000 shares $142.31 million -21.9%14.0%2.3 $21.76 12/31/20198,370,000 shares $197.62 million -34.9%17.9%3.1 $23.61 ITCI Short Interest - Frequently Asked Questions What is Intra-Cellular Therapies' current short interest? Short interest is the volume of Intra-Cellular Therapies shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 2,360,000 shares of ITCI short. Learn More on Intra-Cellular Therapies' current short interest. What is a good short interest ratio for Intra-Cellular Therapies? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ITCI shares currently have a short interest ratio of 4.0. Learn More on Intra-Cellular Therapies's short interest ratio. Which institutional investors are shorting Intra-Cellular Therapies? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Intra-Cellular Therapies: Jane Street Group LLC, Wolverine Trading LLC, Walleye Trading LLC, and Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Intra-Cellular Therapies' short interest increasing or decreasing? Intra-Cellular Therapies saw a decrease in short interest in the month of October. As of October 31st, there was short interest totaling 2,360,000 shares, a decrease of 2.5% from the previous total of 2,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Intra-Cellular Therapies' short interest compare to its competitors? Here is how the short interest of companies compare to Intra-Cellular Therapies: Kura Oncology, Inc. (16.39%), IGM Biosciences, Inc. (16.29%), Ironwood Pharmaceuticals, Inc. (7.03%), Cryoport, Inc. (6.10%), Zentalis Pharmaceuticals, Inc. (9.89%), Prelude Therapeutics Incorporated (13.85%), BioNTech SE (0.84%), Teva Pharmaceutical Industries Limited (1.60%), BeiGene, Ltd. (1.12%), Viatris Inc. (2.09%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Intra-Cellular Therapies stock? Short selling ITCI is an investing strategy that aims to generate trading profit from Intra-Cellular Therapies as its price is falling. ITCI shares are trading up $2.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Intra-Cellular Therapies? A short squeeze for Intra-Cellular Therapies occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ITCI, which in turn drives the price of the stock up even further. How often is Intra-Cellular Therapies' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ITCI, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies KURA Short Interest Data IGMS Short Interest Data IRWD Short Interest Data CYRX Short Interest Data ZNTL Short Interest Data PRLD Short Interest Data BNTX Short Interest Data TEVA Short Interest Data BGNE Short Interest Data VTRS Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ITCI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
